MIL OSI Translation. Region: Russian Federation –
The results of the company’s work in 2021 were discussed, including the development of high-tech products for aircraft construction, medicines and equipment, as well as other projects of the corporation.
From the transcript:
Mikhail Mishustin: Dear Sergey Viktorovich! First of all, I would like to wish you a Happy New Year, Merry Christmas, and wish you and the Rostec staff all the best.
The corporation you are heading develops high-tech products for a whole segment of the Russian economy, for our industry. This is in many ways a world-class technology, including for such an important industry for the entire country as aircraft construction.
This is a priority direction for the state. The President set very important tasks to improve the competitiveness and reliability of Russian aircraft and helicopters.
During our trips around the country, we visited the leading airlines in the industry. These were Ulyanovsk, where today the Il-76 is produced at Aviastar, where, among other things, the An-124 is repaired and serviced. Already composite wings from “Alabuga” are brought there and assembled. This is a very difficult story that ended with the implementation of all the plans of Rostec and the country: today we have actually replaced the wing, which is made in Russia from composite materials, from the highest technological elements, and we will make it on the MS-21.
It must be said about UZGA… This is the Urals, Yekaterinburg, where the L-410 and drones are made. An-124 is also being repaired there.
Then we were in Komsomolsk-on-Amure, where the production of Superjet aircraft is launched. More than 200 machines have already been made. We have seen what a tremendous amount of work has been done to provide him with both spare parts and service. This is a high-class aircraft that today flies reliably on various routes.
Irkutsk – MS-21. We saw with you how production is expanding and scaling. This is a huge amount of work that has been done by the corporation. To date, almost everything has been established in order to start large-scale production of these aircraft.
And of course, a recent trip to Permian, where we saw with you how engines for wide-body heavy aircraft are also produced.
I believe, Sergei Viktorovich, that we need to hold a final meeting in order to fulfill all the tasks that the President has set for us, so that we have already completed all the necessary measures related to the ten-year plan of state orders for civil aviation.
It is very important for us to reduce the degree of dependence on foreign materials and components in domestic aircraft, as in many other industries. And of course, it is important to pay special attention here to the production of your electronic base, you are also actively involved in this.
I would also like you to talk about one of the significant areas of the corporation’s activity – the production of its own high-quality medical products. Including the release of effective and safe vaccines that help protect children and adults from many dangerous diseases.
Please tell us about the results of the year and what the corporation is doing.
Sergei Chemezov: First of all, Mikhail Vladimirovich, I would like to thank you for the attention that you and the Government are showing to the development of industry throughout Russia and the projects being implemented by the Rostec corporation.
You have already said that we visited you together quite recently at the Perm plant, which produces modern engines for our aviation. I would like to thank you once again for the decision to allocate an additional 44.6 billion rubles for the preparation of pilot production, for the creation of a bench base for the development of a new, modern PD-35 engine. This is a high-thrust engine. For the first time in the history of aircraft construction, we have created such an engine; it will be used in the future on wide-body aircraft and on large transport heavy aircraft.
The PD-14 engine has proven itself well, it has already passed the certification. For the first time, we raised an airplane with our engine and showed it at MAKS, took it to Dubai at the Airshow, where it also showed its capabilities. And many of our potential buyers paid great attention to it.
As far as the MS-21 is concerned, last December we raised our aircraft for the first time, as you just said, with our composite wing. And starting from 2022, in 2023 we will be testing this aircraft with our wing and with our engine. And in 2024, the serial production of completely Russian-made aircraft and Russian-made engines will already begin.
In 2022, we will release the first production vehicles. So far, unfortunately, on American engines, but with our wing already. Certification will be completed in December (maybe it will take place a little in January), but we will already release four cars – the first serial ones – and transfer them to operators, our airlines.
In 2023, we are planning to have six cars, then 12, by 2025 we should reach 32 cars. And in 2027 – for 76 cars.
In this regard, thank you very much for instructing the Ministry of Industry and Trade to prepare a roadmap for the delivery of MC-21 aircraft to our airlines for the next decade. Not so long ago, a meeting was held with the President on the development of civil aviation, and a decision was made to subsidize leasing rates for airlines that purchase Russian aircraft. These funds must come from the National Wealth Fund.
Another promising development is PD-8. It is planned to complete its certification in 2023, and in 2024 we will also begin mass production and install it on the Sukhoi Superjet. That is, by 2024, our Sukhoi Superjet will be completely Russian. I’m not saying that we will completely abandon the SaM146, no, depending on the wishes of the airlines that will purchase these aircraft, we will offer different options – either with the SaM146 engine, or with our engine.
We plan to install the PD-8 engine on the Be-200 amphibious aircraft. This is an aircraft that is in great demand today due to, among other things, fires.
Mikhail Mishustin: This is a very important topic, because representatives of other countries apply, especially when the summer is dry, firefighting, and we, of course, need to speed up this work.
S. Chemezov: A few words about Superjets. We have more than 170 aircraft in operation and a little over 20 have been produced, and in the near future we will be transferring them to airlines such as Rossiya, Red Wings and Azimut. By the way, Azimut operates exclusively Superjets and has achieved very good results. They have one aircraft flying up to eight to nine hours a day, which is, in general, a very good indicator, regardless of the aircraft produced in any other companies. And I hope that the positive experience of this company will contribute to the expansion of the use of this aircraft by other Russian airlines.
Rostec quickly came to the rescue of the domestic health care system, which was at the forefront in the fight against coronavirus. During the first year of the pandemic, we produced over 200 thousand units of various medical equipment. These are not only ventilators, but also air disinfectants, non-contact thermometers, thermal imagers and much more. Also delivered over 370 million units of personal protective equipment.
In 2021, the specialists of our Shvabe holding presented a device for extracting oxygen from the surrounding atmosphere, sterilizing it and delivering it in pure form as medical oxygen. We understand that there is some problem in the production of medical oxygen, and in this regard, we have created an apparatus that extracts, purifies and produces medical oxygen from the air. These devices can be connected to a ventilator almost anywhere and not depend on whether it is possible to deliver medical oxygen there or not.
In the middle of the year we will complete the state registration of this apparatus. And we plan that by the end of the year we will start producing up to 100 devices, and from next year there will be more than 200.
Shvabe also created a device for detecting toxins, bacteria and viruses in the air, including COVID-19. These are “Detector-BIO” and “Ether-BIO”. They were created in partnership with the Gamaleya Center and the Institute of Theoretical and Experimental Biophysics of the Academy of Sciences within the framework of the federal target program “The National System of Chemical and Biological Safety of Russia”. So far, the devices are being tested, but they are already showing good results.
Building on our experience, we implement projects for the construction of large turnkey medical centers. So, at the end of December, we handed over ahead of schedule, a year earlier, the medical radiological building at the oncological dispensary in Magadan. About half of the equipment installed there was produced at our Shvabe enterprise.
In April last year, our Natsimbio immunobiological holding registered an innovative direct-acting drug – Covid Globulin. This is a drug created from the blood plasma of people who have had covid disease and have antibodies. It became the first drug of this type in the world, and we have registered it. Its active ingredient is specific antibodies to current variants of the coronavirus. Even regardless of what type of coronavirus currently exists, if a person has previously been ill, “Covid Globulin” will act against a new strain of this virus.
This drug is manufactured at our facility in Perm. We have a large modern enterprise there, modern technologies. I hope that the drug will be put into operation in our clinics in the near future.
In addition, in 2021, the Natsimbio holding was identified as the sole contractor for state contracts for the supply of domestic vaccines for the prevention of coronavirus infection. We have successfully delivered more than 100 and a half million doses to all regions of the country, regardless of where this or that clinic is located: from Kamchatka, the Kuriles, and so on – to Kaliningrad. The longest delivery period for us was three, maximum four days.
Natsimbio has also successfully ensured the supply of domestic vaccines of the national vaccination calendar to all regions of the Russian Federation in the amount of more than 100 million doses. Including 60 million doses of vaccines for the prevention of influenza, 16 of which are a new quadrivalent influenza vaccine “Ultrix Quadri”. It was produced this year one and a half times more than in 2020. We created it in 2019. This is the first vaccine of this level. Previously, these vaccines were mainly purchased overseas. We have created such a vaccine at our own expense, and it is being successfully used today for the prevention of influenza.
Mikhail Mishustin: Thank you, Sergey Viktorovich. Once again you with a holiday, a Happy New Year.
EDITOR’S NOTE: This article is a translation. Apologies should the grammar and or sentence structure not be perfect.